The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway
Top Cited Papers
Open Access
- 13 October 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 6 (10) , e1000161
- https://doi.org/10.1371/journal.pmed.1000161
Abstract
Chand Khanna and colleagues describe the work of the Comparative Oncology Trials Consortium (COTC), which provides infrastructure and resources to integrate naturally occurring dog cancer models into the development of new human cancer drugs, devices, and imaging techniques.Keywords
This publication has 31 references indexed in Scilit:
- Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer VasculaturePLOS ONE, 2009
- Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utilityEuropean Journal Of Cancer, 2008
- Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionshipChromosome Research, 2008
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?Health Affairs, 2006
- The Basic Biology of Malignant Melanoma: Molecular Mechanisms of Disease Progression and Comparative AspectsJournal of Veterinary Internal Medicine, 2003
- The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” DecisionJournal of Clinical Oncology, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Analysis of the equine tumor suppressor gene p53 in the normal horse and in eight cutaneous squamous cell carcinomasCancer Letters, 1996